Andjelka Stones/Pinterest
Jun 5, 2026, 15:53
Andjelka Stones: Key Findings on Hemophilia A Gene Therapy
Andjelka Stones, Former Distinguished Adjunct Professor at NorthCentral University, shared a post on LinkedIn:
“Hemophilia A Gene Therapy
Gene therapy for hemophilia A: 4‑year data from the Phase 3 GENEr8‑1 trial are out.
Key findings (n=134):
- Mean treated bleed rate 82.6% from baseline
- Factor VIII infusion rate 95.5%
- 73.6% of patients had zero treated bleeds in year 4
- Mean FVIII activity at year 4: 16.1 IU/dL
- Only 18% of patients resumed prophylaxis
No new safety signals were observed. Health‑related quality of life remained improved.
This is the longest and largest Phase 3 follow‑up of a gene therapy in hemophilia.
Durable benefit after a single infusion.
Full citation in my archive.”
Stay updated with Hemostasis Today.
-
Nov 17, 2026, 15:26Hereditary Hemorrhagic Telangiectasia: The Molecular Connection Between Vascular Malformations and Bleeding
-
Nov 17, 2026, 14:54Cindy Neunert: Beyond Platelet Counts – Addressing Fatigue and Whole-Person Care in ITP
-
Nov 17, 2026, 14:44Strengthening Haemophilia Diagnosis Through Hands-On Laboratory Training – IAHAD
-
Nov 17, 2026, 14:40Platelet Membrane Protrusions Beyond Their Role in Hemostasis – JTH
-
Nov 17, 2026, 14:10Wolfgang Miesbach: Aspirin vs Anticoagulants – Who Needs More Than Aspirin?
-
Nov 17, 2026, 14:08Chaza Alaji: Soluble Transferrin Receptor – A Key to Uncovering Hidden Iron Deficiency
-
Nov 17, 2026, 14:03Shadi Tabibian: Fibrinogen – From Molecular Structure to Clinical Decision Making
-
Nov 17, 2026, 13:54Gabrielle Sarlon: Breaking the Silence on Menstrual Bleeding During Anticoagulant Therapy
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome